SpotitEarly Knowledge Center

SpotitEarly plans to scale its technology to meet a growing global user base through the modular design of its LUCID platform. The approach combines automation, standardized VOC analysis, and patient-friendly sample collection. With adaptability for diverse environments and a focus on accessibility, SpotitEarly ensures consistent quality, efficiency, and reach in expanding cancer detection worldwide.

Obtaining and maintaining a CLIA certificate is required for laboratories that perform high complexity testing in the United States. This article explains what CLIA oversight involves and how SpotitEarly complies with these standards in its CLIA-registered lab. By meeting federal requirements for quality and accuracy, SpotitEarly ensures its Laboratory Developed Tests are performed in a safe, reliable, and clinically valid manner.

The cancer detection industry is undergoing rapid transformation, driven by demand for earlier diagnosis, multi-cancer technologies, and AI integration. This article explores the trends shaping the field, from liquid biopsy development to accessibility challenges, and highlights how SpotitEarly addresses these gaps. With a bio-AI breath test platform detecting VOCs at early stages, SpotitEarly combines accuracy, accessibility, and transparency to help lead the cancer detectio

Cancer screening today is effective but limited, with most cancers lacking recommended tests. This article compares traditional methods like mammography and colonoscopy with new liquid biopsy approaches and introduces SpotitEarly’s breath-based test. By detecting volatile organic compounds (VOCs) through a bio-hybrid platform that combines canine olfaction with AI, SpotitEarly is advancing a non-invasive, accurate solution that complements current screening and expands early

Breath analysis is transforming the landscape of early cancer detection. By identifying volatile organic compounds (VOCs) in exhaled air, this non-invasive method can reveal disease indicators long before symptoms appear. This article explains the science behind breath-based biomarkers, how SpotitEarly integrates them with canine scent detection and AI, and why this approach offers accuracy, comfort, and scalability for global screening.

SpotitEarly welcomed Dr. J. Leonard “Len” Lichtenfeld as its first Chief Medical Officer to help accelerate early cancer detection. This article outlines his career leadership at the American Cancer Society, his vision for catching cancer earlier, and his priorities at SpotitEarly: advancing rigorous clinical research, building partnerships across healthcare, and securing the resources to scale access to innovative, non‑invasive screening worldwide.

SpotitEarly is developing a revolutionary approach to early cancer detection, combining the natural scent detection abilities of trained dogs with advanced AI analysis. This article introduces the company’s mission, technology, and vision for a future where non-invasive, accurate, and accessible screening is available worldwide. Learn how this hybrid platform aims to make early detection more effective and widely adopted.

As SpotitEarly’s COO and co-founder, Udi Bobrovsky oversees the operational and strategic direction of the company’s early cancer detection platform. In this interview, he shares how his background in tech entrepreneurship and digital health drives the company’s mission, his approach to scaling a hybrid canine-AI screening system, and why he believes innovation and collaboration are key to transforming cancer detection globally.

SpotitEarly is powered by a remarkable team of scientists, engineers, clinicians, and canine specialists, all united by a mission to transform early cancer detection. In this post, meet the innovators behind the test — from the co-founders to the AI developers, dog trainers, and clinical leaders — and learn how their expertise and collaboration make SpotitEarly’s hybrid detection model a global breakthrough in non-invasive cancer screening.

SpotitEarly’s mission is to bring accurate, non-invasive cancer screening to people across the globe. In this post, we explore how our unique bio-AI hybrid approach, combining breath analysis with trained canine detection and artificial intelligence, is making early detection accessible, scalable, and effective. Learn how we’re fighting cancer by reaching more people, earlier, and saving lives.